Burning Rock Biotech (ADR) (BNR)
NGS oncology testing, hospital workflows, and biopharma development services.
Something off on this page? Send us feedback.
Sells NGS-based oncology tests, hospital testing products and support, and development and testing services to pharmaceutical customers. Revenue spans a central laboratory, hospital-based testing operations, and pharma R&D services, while early-detection technology remains in clinical validation.
Combines NGS-based cancer therapy-selection and prognosis testing with minimal-residual-disease monitoring, early-detection research, and assay-development services for pharmaceutical customers. OncoScreen and OncoCompass guide treatment selection from tissue and liquid-biopsy samples; CanCatch supports recurrence monitoring. OverC, the multi-cancer early-detection program, remains in clinical validation rather than an established commercial line.
Monetizes completed tests through a central laboratory, products and workflow support through hospital laboratories, and contracted development and testing work for biopharma customers. Operations and commercial activity are centered in China, with a move toward in-hospital testing and pharma R&D services. Adoption depends on physician ordering, hospital workflow uptake, applicable diagnostic approvals, affordability, reimbursement, and pharma project timing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $62.5M · Total debt $6.7M · Total assets $111.9M · Shareholders' equity $74.1M
- Revenue
- $20.1M
- Operating income
- −$2.7M
- Net income
- −$2.7M
Reported in CNY, converted at the latest exchange rate
No dividends on record.
| Institutions | 164.25% | 1.74M ADS | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Adds to | 164.25% | ||
1.06M ADS as of Aug 25, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
These groups come from separate filings that can overlap, so they add to 164.25%; nothing is left for Other.
This company has 3 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kynam Capital Management, LPInstitution | 117.18% | 1.24M A ADS | as of Jun 30, 2026 |
CRCM LPInstitution | 20.06% | 211,997 A ADS | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 5.00% | 52,838 A ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 4.12% | 43,594 A ADS | as of Jun 30, 2026 |
Nikko Asset Management Americas, Inc.Institution | 2.81% | 29,724 A ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | Yusheng Han | director | +24,760 | $8.74 |
| Jun 12, 2026 | Yusheng Han | director | +210,000 | $9.25 |
| Jun 16, 2026 | Yusheng Han | director | +111,110 | $9.00 |
| Jun 22, 2026 | Yusheng Han | director | +104,650 | $7.45 |
| Jun 23, 2026 | Yusheng Han | director | +5,990 | $7.50 |
- Guardant Health
Liquid-biopsy profiling and companion diagnostics for advanced cancer.
- Caris Life Sciences
Broad tissue and blood molecular profiling, MRD, and early detection.
- Tempus AI
Oncology genomic diagnostics combined with hospital and pharma data tools.
- NeoGenomics
Oncology reference-lab testing with molecular profiling and pharma services.
- Natera
Tumor-informed ctDNA monitoring for MRD and cancer recurrence.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Burning Rock Biotech (ADR) | $16.48 | +0.18% | $17.4M | — | — | 0.2 | +6.6% |
| Guardant Health | $177.98 | +0.46% | $23.77B | — | — | 20.1 | +44.3% |
| Caris Life Sciences | $32.49 | +3.23% | $8.90B | 87.9 | 129.0 | 9.0 | +45.4% |
| Tempus AI | $77.22 | +0.04% | $13.52B | — | — | 9.4 | +21.6% |
| NeoGenomics | $18.79 | −0.53% | $485.4M | — | 67.6 | 0.6 | +11.2% |
| Natera | $388.06 | −0.73% | $55.98B | — | — | 20.7 | +37.7% |
| Median | 87.9 | 98.3 | 9.4 | +37.7% |